{"id":68784,"date":"2026-06-24T00:27:11","date_gmt":"2026-06-23T16:27:11","guid":{"rendered":"https:\/\/flcube.com\/?p=68784"},"modified":"2026-06-24T00:27:30","modified_gmt":"2026-06-23T16:27:30","slug":"biokin-secures-worlds-first-egfrxher3-bispecific-adc-approval-with-loncomystatug-deruxtecan-for-nasopharyngeal-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68784","title":{"rendered":"Biokin Secures World&#8217;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that its <strong>first-in-class (FIC) Class 1 therapeutic biologic<\/strong>, <strong>loncomystatug deruxtecan (BL-B01D1\/iza-bren)<\/strong>, has received <strong>marketing approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for <strong>recurrent\/metastatic nasopharyngeal carcinoma (NPC)<\/strong> in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\/PD-L1 inhibitor.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-details\" class=\"wp-block-heading\">Regulatory Milestone Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Loncomystatug deruxtecan (BL-B01D1\/iza-bren)<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>June 23, 2026<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Recurrent\/metastatic NPC (\u22652 prior chemo lines + PD-1\/PD-L1 inhibitor failure)<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>First-in-class (FIC) Class 1 therapeutic biologic<\/td><\/tr><tr><td><strong>Global Significance<\/strong><\/td><td><strong>World&#8217;s first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC)<\/strong> approved for marketing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-innovation-profile\" class=\"wp-block-heading\">Product Innovation Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC)<\/strong> targeting dual receptor pathways simultaneously<\/li>\n\n\n\n<li><strong>Therapeutic Breakthrough:<\/strong> Represents the first successful clinical application of bispecific ADC technology combining EGFR and HER3 targeting<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Addresses high-unmet need in heavily pre-treated NPC patients with limited therapeutic options<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Over <strong>40 clinical trials<\/strong> conducted across China and the United States<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-portfolio\" class=\"wp-block-heading\">Clinical Development Portfolio<\/h2>\n\n\n\n<h3 id=\"h-advanced-trial-portfolio\" class=\"wp-block-heading\">Advanced Trial Portfolio:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>19 Phase III studies<\/strong> (including Phase II\/III) across multiple tumor types<\/li>\n\n\n\n<li><strong>7 NMPA Breakthrough Therapy Designations<\/strong> for various indications<\/li>\n\n\n\n<li><strong>2 NMPA Priority Reviews<\/strong> granted<\/li>\n\n\n\n<li><strong>1 FDA Breakthrough Therapy Designation<\/strong> in the United States<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-additional-nda-submissions-pending\" class=\"wp-block-heading\">Additional NDA Submissions Pending:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Recurrent or metastatic esophageal squamous cell carcinoma<\/strong><\/li>\n\n\n\n<li><strong>Locally advanced or metastatic triple-negative breast cancer<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Successful approval validates Biokin&#8217;s bispecific ADC platform technology with potential applications across multiple solid tumors<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Dual EGFR\u00d7HER3 targeting provides unique mechanism compared to single-target ADCs and traditional therapies<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> NPC represents significant market opportunity in Asia, with peak annual sales potential estimated at \u00a52\u20133 billion ($280\u2013420 million) in China alone<\/li>\n\n\n\n<li><strong>Global Expansion Pathway:<\/strong> FDA Breakthrough Therapy Designation supports international development strategy beyond China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-context\" class=\"wp-block-heading\">Development Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This approval represents a major milestone for Chinese biotechnology innovation, demonstrating the capability to develop world-first bispecific ADC technologies. The extensive clinical program spanning 40 trials across two continents reflects Biokin&#8217;s commitment to comprehensive global development standards while addressing regionally prevalent cancers like nasopharyngeal carcinoma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The rapid regulatory progression\u2014supported by multiple breakthrough designations and priority reviews\u2014highlights the significant unmet medical need in recurrent\/metastatic NPC and the compelling clinical profile of loncomystatug deruxtecan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ materially due to risks including market adoption rates, competitive dynamics, manufacturing scalability, and clinical trial outcomes in additional indications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260623_3YRL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260623_3YRL.\"><\/object><a id=\"wp-block-file--media-67fe239b-90a4-4569-88ad-85075b97372c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260623_3YRL.pdf\">688506_20260623_3YRL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260623_3YRL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-67fe239b-90a4-4569-88ad-85075b97372c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,151,15,857],"class_list":["post-68784","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-product-approvals","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biokin Secures World&#039;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1\/iza-bren), has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for recurrent\/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\/PD-L1 inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68784\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biokin Secures World&#039;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1\/iza-bren), has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for recurrent\/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\/PD-L1 inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68784\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T16:27:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T16:27:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68784#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68784\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biokin Secures World&#8217;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma\",\"datePublished\":\"2026-06-23T16:27:11+00:00\",\"dateModified\":\"2026-06-23T16:27:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68784\"},\"wordCount\":436,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Product approvals\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68784#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68784\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68784\",\"name\":\"Biokin Secures World's First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-23T16:27:11+00:00\",\"dateModified\":\"2026-06-23T16:27:30+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1\\\/iza-bren), has received marketing approval from China's National Medical Products Administration (NMPA) for recurrent\\\/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\\\/PD-L1 inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68784#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68784\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68784#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biokin Secures World&#8217;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biokin Secures World's First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1\/iza-bren), has received marketing approval from China's National Medical Products Administration (NMPA) for recurrent\/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\/PD-L1 inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68784","og_locale":"en_US","og_type":"article","og_title":"Biokin Secures World's First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1\/iza-bren), has received marketing approval from China's National Medical Products Administration (NMPA) for recurrent\/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\/PD-L1 inhibitor.","og_url":"https:\/\/flcube.com\/?p=68784","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-23T16:27:11+00:00","article_modified_time":"2026-06-23T16:27:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68784#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68784"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biokin Secures World&#8217;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma","datePublished":"2026-06-23T16:27:11+00:00","dateModified":"2026-06-23T16:27:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68784"},"wordCount":436,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Product approvals","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68784#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68784","url":"https:\/\/flcube.com\/?p=68784","name":"Biokin Secures World's First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-23T16:27:11+00:00","dateModified":"2026-06-23T16:27:30+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1\/iza-bren), has received marketing approval from China's National Medical Products Administration (NMPA) for recurrent\/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1\/PD-L1 inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68784#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68784"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68784#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biokin Secures World&#8217;s First EGFR\u00d7HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68784"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68784\/revisions"}],"predecessor-version":[{"id":68787,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68784\/revisions\/68787"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}